MX2019007891A - Sales de oxalato de tianeptina y polimorfos. - Google Patents
Sales de oxalato de tianeptina y polimorfos.Info
- Publication number
- MX2019007891A MX2019007891A MX2019007891A MX2019007891A MX2019007891A MX 2019007891 A MX2019007891 A MX 2019007891A MX 2019007891 A MX2019007891 A MX 2019007891A MX 2019007891 A MX2019007891 A MX 2019007891A MX 2019007891 A MX2019007891 A MX 2019007891A
- Authority
- MX
- Mexico
- Prior art keywords
- polymorphs
- tianeptine
- oxalate salts
- tianeptine oxalate
- oxalate
- Prior art date
Links
- 229960005138 tianeptine Drugs 0.000 title abstract 3
- -1 Tianeptine oxalate salts Chemical class 0.000 title 1
- JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 abstract 2
- ZTHVLZXTYSAELD-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-11h-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid Chemical compound CN1SC2=CC(Cl)=CC=C2C(NCCCCCCC(O)=O)C2=CC=CC=C12 ZTHVLZXTYSAELD-UHFFFAOYSA-N 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 150000003891 oxalate salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662439533P | 2016-12-28 | 2016-12-28 | |
| PCT/IB2017/001709 WO2018122606A1 (en) | 2016-12-28 | 2017-12-28 | Tianeptine oxalate salts and polymorphs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007891A true MX2019007891A (es) | 2019-12-16 |
Family
ID=61283255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007891A MX2019007891A (es) | 2016-12-28 | 2017-12-28 | Sales de oxalato de tianeptina y polimorfos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10449203B2 (enExample) |
| EP (1) | EP3562812A1 (enExample) |
| JP (2) | JP2020503330A (enExample) |
| CN (1) | CN110418785A (enExample) |
| AU (1) | AU2017385958B2 (enExample) |
| BR (1) | BR112019013244A2 (enExample) |
| CA (1) | CA3048324A1 (enExample) |
| IL (1) | IL267708A (enExample) |
| MX (1) | MX2019007891A (enExample) |
| MY (1) | MY199385A (enExample) |
| NZ (1) | NZ754797A (enExample) |
| WO (1) | WO2018122606A1 (enExample) |
| ZA (1) | ZA201904185B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ754797A (en) * | 2016-12-28 | 2022-05-27 | Tonix Pharma Holdings Ltd | Tianeptine oxalate salts and polymorphs |
| US20240165126A1 (en) | 2021-03-15 | 2024-05-23 | Tonix Pharmaceuticals Holding Corp. | Tianeptine oxalate and naloxone combination for the treatment of major depressive disorder |
| CN117769540A (zh) * | 2021-05-11 | 2024-03-26 | 亚士德制药公司 | 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3758528A (en) * | 1970-03-13 | 1973-09-11 | Science Union & Cie | Tricyclic compounds |
| FR2635461B1 (fr) * | 1988-08-18 | 1992-01-17 | Adir | Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress |
| US5405842A (en) | 1994-01-28 | 1995-04-11 | Silverman; Bernard A. | Treatment of steroid dependent asthmatics |
| FR2791891A1 (fr) | 1999-04-07 | 2000-10-13 | Adir | Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence |
| TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
| US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
| US8198268B2 (en) * | 2008-10-31 | 2012-06-12 | Janssen Biotech, Inc. | Tianeptine sulfate salt forms and methods of making and using the same |
| NZ754797A (en) * | 2016-12-28 | 2022-05-27 | Tonix Pharma Holdings Ltd | Tianeptine oxalate salts and polymorphs |
-
2017
- 2017-12-28 NZ NZ754797A patent/NZ754797A/en not_active IP Right Cessation
- 2017-12-28 WO PCT/IB2017/001709 patent/WO2018122606A1/en not_active Ceased
- 2017-12-28 MX MX2019007891A patent/MX2019007891A/es unknown
- 2017-12-28 US US15/856,818 patent/US10449203B2/en active Active
- 2017-12-28 AU AU2017385958A patent/AU2017385958B2/en not_active Ceased
- 2017-12-28 CN CN201780085697.9A patent/CN110418785A/zh active Pending
- 2017-12-28 CA CA3048324A patent/CA3048324A1/en active Pending
- 2017-12-28 JP JP2019535330A patent/JP2020503330A/ja active Pending
- 2017-12-28 MY MYPI2019003711A patent/MY199385A/en unknown
- 2017-12-28 EP EP17844642.3A patent/EP3562812A1/en not_active Withdrawn
- 2017-12-28 BR BR112019013244A patent/BR112019013244A2/pt not_active IP Right Cessation
-
2019
- 2019-06-26 ZA ZA2019/04185A patent/ZA201904185B/en unknown
- 2019-06-27 IL IL267708A patent/IL267708A/en unknown
- 2019-10-09 US US16/597,065 patent/US10946027B2/en active Active
-
2022
- 2022-11-10 JP JP2022180549A patent/JP2023001340A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10449203B2 (en) | 2019-10-22 |
| AU2017385958B2 (en) | 2021-12-02 |
| CN110418785A (zh) | 2019-11-05 |
| MY199385A (en) | 2023-10-25 |
| US10946027B2 (en) | 2021-03-16 |
| WO2018122606A1 (en) | 2018-07-05 |
| US20200276208A1 (en) | 2020-09-03 |
| JP2023001340A (ja) | 2023-01-04 |
| NZ754797A (en) | 2022-05-27 |
| EP3562812A1 (en) | 2019-11-06 |
| ZA201904185B (en) | 2021-10-27 |
| AU2017385958A1 (en) | 2019-07-11 |
| IL267708A (en) | 2019-08-29 |
| US20180338984A1 (en) | 2018-11-29 |
| CA3048324A1 (en) | 2018-07-05 |
| JP2020503330A (ja) | 2020-01-30 |
| BR112019013244A2 (pt) | 2019-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| UY35683A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| ZA201804870B (en) | Acid addition salts of piperazine derivatives | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| MX354021B (es) | Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona. | |
| PH12017502171B1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
| PH12015502018A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| CL2017002179A1 (es) | Sales de inhibidor de pi3k y procesos de preparación | |
| MX370390B (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
| EA201591804A1 (ru) | Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы | |
| EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
| MX359673B (es) | Preparacion de intermediarios de pirimidina utiles para la preparacion de maci tentano. | |
| NZ712660A (en) | Dicarboxylic acid compound | |
| MY199385A (en) | Tianeptine oxalate salts and polymorphs | |
| GEP201706655B (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| JOP20170164A1 (ar) | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري | |
| BR112017007027A2 (pt) | melhorias nos compostos orgânicos ou relativas aos mesmos | |
| AR092772A1 (es) | Derivado de 7-azaindol | |
| MX2016010564A (es) | Procesos para preparar moduladores del canal ionico heterociclico fusionado. | |
| BR112017004166A2 (pt) | sal de derivado de cefalosporina, forma sólida cristalina do mesmo e método para produzir o mesmo | |
| BR112015017919A8 (pt) | preparação líquida aquosa e método para clarificar uma preparação líquida aquosa |